The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis.

Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. · 2019

Read The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis. by Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6458841.txt.

Introduction

Fransquet and co-authors review whether epigenetic clocks, gauges of body age built from DNA marks, predict disease and death beyond a person's years. They combined 23 studies with 41,607 people in all, spanning long life, cancer, heart disease, dementia, and death. Age acceleration, testing older than one's real age, was the measure of interest.

Links to disease showed up but on and off, and few studies repeated the same design. Death told a firmer story: each five-year rise in clock age carried an 8 to 15 percent higher risk of death across the two clock meta-analyses. Skew in what gets published may inflate even that, so the authors stop short of backing clinic use.

Catalog record

CREATORFransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6458841

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis By Peter D Fransquet, Jo Wrigglesworth, Robyn L Woods, Michael E Ernst, Joanne Ryan Published in: Clinical Epigenetics DOI: 10.1186/s13148-019-0656-7 ABSTRACT Abstract Background Ageing is one of the principal risk factors for many chronic diseases. However, there is considerable between-person variation in the rate of ageing and individual differences in their susceptibility to disease and death. Epigenetic mechanisms may play a role in human ageing, and DNA methylation age biomarkers may be good predictors of age-related diseases and mortality risk. The aims of this systematic review were to identify and synthesise the evidence for an association between peripherally measured DNA methylation age and longevity, age-related disease, and mortality risk. Methods A systematic search was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Using relevant search terms, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsychINFO databases were searched to identify articles meeting the inclusion criteria. Studies were assessed for bias using Joanna Briggs Institute critical appraisal checklists. Data was extracted from studies measuring age acceleration as a predictor of age-related diseases, mortality or longevity, and the findings for similar outcomes compared. Using Review Manager 5.3 software, two meta-analyses (one per epigenetic clock) were conducted on studies measuring all-cause mortality. Results Twenty-three relevant articles were identified, including a total of 41,607 participants. Four studies focused on ageing and longevity, 11 on age-related disease (cancer, cardiovascular disease, and dementia), and 11 on mortality. There was some, although inconsistent, evidence for an association between increased DNA methylation age and risk of disease. Meta-analyses indicated that each 5-year increase in DNA methylation age was associated an 8 to 15% increased risk of mortality. Conclusion Due to the small number of studies and heterogeneity in study design and outcomes, the association between DNA methylation age and age-related disease and longevity is inconclusive. Increased epigenetic age was associated with mortality risk, but positive publication bias needs to be considered. Further research is needed to determine the extent to which DNA methylation age can be used as a clinical biomarker. Electronic supplementary material The online version of this article (10.1186/s13148-019-0656-7) contains supplementary material, which is available to authorized users. Keywords: Ageing, Age-related disease, Biological age, DNA methylation, Epigenetic clock, Longevity, Mortality, Systematic review BACKGROUND The population is ageing [1, 2], and age is one of the strongest risk factors for many human diseases, such as cardiovascular, metabolic and neurological diseases, and cancer [3]. This increased burden represents a major societal, economic, and public health challenge. Individuals, however do not all age to the same extent. There is considerable between-person variation in the rate of ageing, and individual differences in their susceptibility to disease and death. The identification of individuals at greatest risk of age-related diseases and death would provide important opportunities for targeting prevention and intervention. There is thus great interest in molecular targets as clinical biomarkers which accurately predict the risk of age-related diseases and mortality. These biomarkers, which include cellular senescence, genomic instability, telomere attrition, and mitochondrial dysfunction, appear to capture pivotal aspects of biological age [4] and have been associated with a number of age-related diseases and mortality. It is well established that as individuals age, there is a raft of molecular changes that occur within the cells and tissues. Changes in DNA methylation patterns have been shown to occur with ageing [5] and thus may be a fundamental mechanism that drives human ageing [6]. Epigenetic biomarkers of ageing, otherwise known as the epigenetic clock, have been developed using DNA methylation measurements. Referred to specifically as ‘DNA methylation age’ (DNAmAge), they provide an accurate estimate of age across a range of tissues, and at different stages of life [7, 8], and are some of the most promising biomarkers of ageing [9, 10]. DNAmAge has also permitted the identification of individuals who show substantial deviations from their actual chronological age, and this ‘accelerated biological aging’ has been associated with unhealthy behaviours [11], frailty [12], cancer [13], diabetes [14], cardiovascular diseases (CVD) [15], dementia [16], and mortality risk [17]. In the last few years, two meta-analyses of 13 studies (n = 13,089) and 4 studies (n = 4658), respectively, have been undertaken to investigate the extent to which DNAmAge in blood predicts mortality risk [17, 18]. Both reported a significant association between increased DNAmAge and mortality risk. However, neither was undertaken as part of a systematic review, raising the possibility that the findings were not representative of all research that has been undertaken in the field. To date, there has also been no systematic review that has investigated whether DNAmAge biomarkers are predictors of age-related diseases or longevity. The aim of this systematic review is to identify and synthesise the evidence for an association between DNAmAge measured in peripheral tissues (blood, saliva, buccal cells), and longevity, age-related disease, and mortality risk. METHODS This systematic review protocol was registered as number CRD42018108568 on the international website for systematic reviews, PROSPERO (the International Prospective Register of Ongoing Systematic Reviews) [19]. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (http://www.prisma-statement.org) [20, 21] were closely adhered to in the preparation of this systematic review. Inclusion criteria Types of studies and participants Cross-sectional studies, prospective cohorts, and case-control studies were eligible for inclusion in this review. Studies involving humans of any age, gender, race and ethnicity, and who were recruited from either the general community or a specific patient group, were eligible for inclusion. Animal studies, in vitro, and in vivo experiments were excluded. Epigenetic clock (DNA methylation age) Studies were eligible for inclusion in this systematic review if they extracted DNA from peripheral biological samples (blood, saliva, buccal swabs) and measured DNA methylation. Studies met our eligibility criteria if they assessed DNAmAge with at least one of the two most widely used and well-validated epigenetic clocks; the Horvath clock [8] and Hannum’s clock [7]. The Horvath estimator is based on DNA methylation at 353 cytosine-phosphate-guanine base pairs (CpGs) [22]. The Hannum estimator is based on DNA methylation at 71 distinct CpGs. To ascertain whether participants are biologically older or younger compared to their actual age, age acceleration (AA) is measured. This is done by determining the difference between an individual’s DNAmAge and their chronological age. There are also some more recent variations to the AA measurements. Specifically, ‘intrinsic epigenetic age acceleration’ (IEAA) takes into account measures of blood cell counts and adjusts for this accordingly [23]. This provides a measure of AA independent of changes in blood cell composition, which can occur with age [24] or in response to immune system functions [23]. Another measure is ‘extrinsic epigenetic age acceleration’ (EEAA) [18], which incorporates the changes in cell composition by using a weighted average of age-associated cell counts. It thus provides a measure of AA that incorporates changes in age-related cell composition. The eligible estimates of DNAmAge acceleration that were included in this review were thus: - Age acceleration calculated with Horvath’s clock (AAH) - Age acceleration calculated with Hannum’s clock (AAHa) - Intrinsic epigenetic age acceleration calculated with Horvath’s clock (IEAAH) - Intrinsic epigenetic age acceleration calculated with Hannum’s clock (IEAAHa) -

Read the complete text